INSIGHTS ON DRUG DEVELOPMENT

  • Closing The QC Gap For mAbs: Rapid Answers Without Compromising
    6/9/2026

    Monoclonal antibodies are complex biologics requiring precise analytical strategies to monitor critical quality attributes and impurities, with molecular assays like qPCR supporting sensitive detection, product integrity, and regulatory compliance.

  • Lentiviral Vector Upstream Process
    12/12/2025

    Scalable lentiviral vector production is moving beyond adherent systems. Learn how streamlined workflows enable linear scale-up in stirred-tank bioreactors for cost-effective gene therapy manufacturing.

  • Using AI-Analysis And High-Content Screening To Improve Data Capturing
    4/4/2025

    Discover an advanced 3D imaging for drug discovery that features high-throughput, high-quality images, modular hardware, and intuitive software for precise, rapid analysis.

  • Maintain Control Of Pharmaceutical Water Systems
    4/10/2026

    Early TOC excursions often reveal hidden risks in water systems. Capturing samples at the moment of deviation helps teams confirm root causes faster, reduce uncertainty, and maintain control.

  • Aggregate Analysis Of Semaglutide
    12/11/2025

    Effective size exclusion chromatography (SEC) for Semaglutide aggregate analysis is possible without high organic solvents or acidic modifiers. Learn about this robust method for improved efficacy.

DRUG DEVELOPMENT SOLUTIONS

  • Ergonomic system microscope Leica DM1000 LED

    The Leica DM1000 LED features long-life LED illumination that provides near daylight, bright illumination with constant color temperature and emits less heat.

    The LED also eliminates the need for lamp changes, which saves time and money. Because of its low power consumption, the system is energy efficient. Users of the Leica DM1000 LED benefit from the system’s ability to uniquely adapt to every user.

    It is ideal for all clinical laboratory applications, especially for cytology, haematology, and pathology. For special diagnostics requirements, the microscope is certified for in-vitro-diagnostics (IVD) like in-vitro-fertilization (IVF).

  • Explore how specialized analytical expertise and advanced instrumentation enable precise nitrosamine testing to help drug developers meet strict and evolving regulatory requirements.

  • Explore how key biomarkers like Amyloid-beta, TAU, and α-Synuclein are transforming neurodegeneration research, with enhanced detection strategies that improve diagnostic accuracy.

  • Curia’s DMPK scientists deliver expert solutions for your drug discovery programs. Providing bioanalytical methods development, in vitro ADMET testing and in vivo PK and PD services that span all stages of drug discovery up to candidate selection.

  • Guided by Quality by Design (QbD) principles, our experienced scientists develop tailored strategies that optimize product performance, manufacturability, stability, and regulatory readiness across all stages of development.